Type
Internal restructuring
Country
Sweden
Region
Stockholm; Stockholms län;
Location of affected unit(s)
Södertälje
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

450 jobs
Number of planned job losses
Job loss
Announcement Date
1 February 2007
Employment effect (start)
Foreseen end date
31 December 2007

Description

Astra Zeneca announced on 1 February that it will cut 450 jobs at its plant in Södertälje before the end of 2007. Further dismissals could be decided within the company's global redundancy plan, which will affect 3,000 workers worlwide over the next three years. The drug maker, which is facing patent challenges and escalating generic competition, revealed the global redundancy plan as part of a 384 million Euro three-year revamp of its supply chain as it said that sales growth would continue at a slower pace this year.

However, on 28 April it was announced that the 450 affected employees might be offered a job at Scania instead. Scania recently moved some of its production from Falun and Sibbhult to Södertälje. However, after the relocation only 100 of the workers from the two affected units have started to work at Scania in Södertälje and the company is short of staff (Scania is creating 1,200 new jobs in Södertälje). Scania is therefore eventually employing new people and, as it was announced on 28 April 2007, the company will employ by the end of the year the workers who have been affected by restructuring at Astra Zeneca.


Sources

  • 1 February 2007: Report by AstraZeneca
  • 1 February 2007: Sveriges Radio
  • 1 February 2007: International Herald Tribune
  • 28 April 2007: Svenska Dagbladet

Citation

Eurofound (2007), Astra Zeneca, Internal restructuring in Sweden, factsheet number 64889, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/64889.